抽象的

Short Review on Dapagliflozin

Vishnu Vardhan

Dapagliflozin is a medication of the gliflozin class, used to treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor. It works by diminishing the measure of sugar the body assimilates and expanding the measure of sugar that leaves the body. Dapagliflozin is utilized alongside diet and work out, and now and again with different drugs, to lower glucose levels in patients with type 2 diabetes (condition in which glucose is too high in light of the fact that the body does not create or utilize insulin ordinarily). Dapagliflozin is in a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It brings down glucose by creating the kidneys to dispose of more glucose. Dapagliflozin is not used to treat type 1 diabetes (condition in which the body does not deliver insulin and, in this manner, can't control the measure of sugar in the blood) or diabetic ketoacidosis (a genuine condition that may create if high glucose is not treated).

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证

索引于

谷歌学术
打开 J 门
研究圣经
引用因子
宇宙IF
开放学术期刊索引 (OAJI)
学者指导
普布隆斯
国际创新期刊影响因子(IIJIF)
国际组织研究所 (I2OR)
宇宙
日内瓦医学教育与研究基金会
秘密搜索引擎实验室
欧洲酒吧

查看更多